{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus&page=2", "query": { "intervention": "Tetanus", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T05:18:24.273Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01644968", "title": "Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Cohort 1 anti-OX40", "type": "DRUG" }, { "name": "Cohort 2 anti-OX40", "type": "DRUG" }, { "name": "Cohort 3 anti-OX40", "type": "DRUG" }, { "name": "Tetanus Day 29", "type": "BIOLOGICAL" }, { "name": "Tetanus Day 1", "type": "BIOLOGICAL" }, { "name": "KLH Day 1", "type": "BIOLOGICAL" }, { "name": "KLH Day 29", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2003-11", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644968" }, { "nct_id": "NCT01588015", "title": "Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Promyelocytic Leukemia (M3)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma", "B-cell Adult Acute Lymphoblastic Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cytomegalovirus Infection", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Isolated Plasmacytoma of Bone", "Monoclonal Gammopathy of Undetermined Significance", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Peripheral T-cell Lymphoma", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Primary Myelofibrosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Multiple Myeloma", "Stage I Small Lymphocytic Lymphoma", "Stage IA Mycosis Fungoides/Sezary Syndrome", "Stage IB Mycosis Fungoides/Sezary Syndrome", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Multiple Myeloma", "Stage IIA Mycosis Fungoides/Sezary Syndrome", "Stage IIB Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Mycosis Fungoides/Sezary Syndrome", "Stage IIIB Mycosis Fungoides/Sezary Syndrome", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Stage IVA Mycosis Fungoides/Sezary Syndrome", "Stage IVB Mycosis Fungoides/Sezary Syndrome", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "tetanus-CMV fusion peptide vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2012-10-29", "completion_date": "2024-02-02", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01588015" }, { "nct_id": "NCT04056117", "title": "A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Shigellosis" ], "interventions": [ { "name": "Shigella 4V", "type": "BIOLOGICAL" }, { "name": "MenACWY", "type": "BIOLOGICAL" }, { "name": "Rabies", "type": "BIOLOGICAL" }, { "name": "Diphtheria, Tetanus and Pertussis (DTaP)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LimmaTech Biologics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Months", "maximum_age": "50 Years", "sex": "ALL", "summary": "8 Months to 50 Years" }, "enrollment_count": 597, "start_date": "2019-09-02", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 0, "location_summary": "Not listed", "locations": [], "official_url": "https://clinicaltrials.gov/study/NCT04056117" }, { "nct_id": "NCT02096263", "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Poliomyelitis", "Diphtheria", "Haemophilus Influenzae Type b", "Tetanus", "Acellular Pertussis", "Hepatitis B" ], "interventions": [ { "name": "Infanrix hexa", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "Pentacel", "type": "BIOLOGICAL" }, { "name": "Engerix-B", "type": "BIOLOGICAL" }, { "name": "Infanrix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Prevnar13", "type": "BIOLOGICAL" }, { "name": "Rotarix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 585, "start_date": "2014-04-16", "completion_date": "2015-11-13", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 43, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096263" }, { "nct_id": "NCT00345579", "title": "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b", "Neisseria Meningitidis" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "Pediarix/Infanrix Penta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 4432, "start_date": "2006-09", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345579" }, { "nct_id": "NCT01439165", "title": "Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tetanus", "Diphtheria", "Pertussis", "Whooping Cough" ], "interventions": [ { "name": "Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus and Diphtheria Toxoids Adsorbed For Adult Use", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 1330, "start_date": "2011-11", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 28 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01439165" }, { "nct_id": "NCT00467519", "title": "Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Diphtheria", "Pertussis" ], "interventions": [ { "name": "Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)", "type": "BIOLOGICAL" }, { "name": "DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 1045, "start_date": "2007-04", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2014-02-07", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00467519" }, { "nct_id": "NCT03562377", "title": "Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tdap vaccine", "type": "BIOLOGICAL" }, { "name": "Meningococcal vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "54 Years", "sex": "ALL", "summary": "18 Years to 54 Years" }, "enrollment_count": 215, "start_date": "2018-07-13", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 39, "location_summary": "Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562377" }, { "nct_id": "NCT03207750", "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rotavirus Infection", "Rotavirus Vaccines" ], "interventions": [ { "name": "Rotarix", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Prevenar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 1280, "start_date": "2017-09-14", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Daly City", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207750" }, { "nct_id": "NCT02209623", "title": "TDAP Safety in Pregnant Women", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pertussis" ], "interventions": [ { "name": "TDAP", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 375, "start_date": "2014-05", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2017-12-20", "last_synced_at": "2026-09-13T05:18:24.273Z", "location_count": 2, "location_summary": "Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02209623" } ] }